Clinical Trial News and Research

RSS

Medgenics to commence EPODURE Biopumps Phase IIa study in ESRD-related anemia

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced receipt of clearance from the Israeli Ministry of Health to initiate a Phase IIa clinical study evaluating the safety and efficacy of sustained erythropoietin therapy produced and delivered by the Company's EPODURE Biopumps.

26 Mar 2012

Nerve pain patients in Wales gain access to first of a kind treatment which can provide lasting pain relief

For the first time NHS patients in Wales with peripheral nerve pain (known as peripheral neuropathic pain) can be treated with a patch containing capsaicin, which can provide at least 12 weeks pain relief following a single 30- or 60-minute application.

25 Mar 2012

Combination of everolimus and exemestane reduces spread of cancer in the bone

Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.

23 Mar 2012

Treatment with aromatase inhibitors enables some women to have lumpectomy

Preoperative treatment with aromatase inhibitors increases the likelihood that postmenopausal women with estrogen receptor-positive breast cancer will be able to have breast-conserving surgery rather than a mastectomy, according to the results of a national clinical trial presented today at the Society of Surgical Oncology annual meeting in Orlando, Fla.

23 Mar 2012

European Commission grants marketing authorization for use of BYETTA with basal insulin

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced today that the European Commission has granted marketing authorization to BYETTA (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

23 Mar 2012

Emergent receives NIAID grant to advance development of MVA85A TB vaccine

Emergent BioSolutions Inc. today announced that it has received a multi-year grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to advance the development of MVA85A, a candidate vaccine against tuberculosis.

23 Mar 2012

Working together to fight TB

In this post in USAID's "IMPACTblog," guest blogger Joanna Breitstein, director of communications for the TB Alliance, describes an event organized by the Critical Paths to TB Drug Regimens that took place on Monday, "heralding the launch of a new clinical trial that tests tuberculosis drugs in combination."

22 Mar 2012

Low bone density drugs may protect women from endometrial cancer

Low bone density medications, such as Fosamax, Boniva and Actonel, may have a protective effect for endometrial cancer, according to a study at Henry Ford Hospital.

22 Mar 2012

Thromboembolic events can occur after musculoskeletal injury and related surgery

Below is a news summary of an orthopaedic research study appearing in the March 21, 2012 issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issues' full Table of Contents.

22 Mar 2012

BHR Pharma enrolls first 400 patients for BHR-100 pivotal trial for TBI

As communities in the United States gather in support of Traumatic Brain Injury (TBI) Awareness Day, BHR Pharma, LLC's SyNAPSe- clinical trial reaches an important enrollment milestone.

22 Mar 2012

Fat-enclosed nanoparticles can directly irradiate brain tumor

For the past 40 years, radiation has been the most effective method for treating deadly brain tumors called glioblastomas. But, although the targeting technology has been refined, beams of radiation still must pass through healthy brain tissue to reach the tumor, and patients can only tolerate small amounts before developing serious side effects.

21 Mar 2012

Two-year results from Boston Scientific's PROMUS Element trial to be presented at ACC 2012

Boston Scientific Corporation releases its schedule of product-related clinical research at the 61th Annual Scientific Session of the American College of Cardiology/i2 Summit, March 24-27 in Chicago.

21 Mar 2012

TACT believes that Halo's HT-100 may effectively treat DMD

Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that the TREAT-NMD Advisory Committee on Therapeutics (TACT) has reviewed HT-100, Halo's drug candidate for Duchenne muscular dystrophy (DMD), and believes the compound has potential based on the proposed mechanism.

21 Mar 2012

TB Alliance launches Phase II clinical trial to test new drug regimen among people with TB, MDR-TB

The TB Alliance on Monday announced it has launched a Phase II clinical trial "of a new treatment regimen for tuberculosis, including for patients with resistance to existing multi-drug programs," Agence France-Presse reports.

21 Mar 2012

Transforming biomedical research to develop TB vaccines

In the past decade, scientists have made significant progress building the critical knowledge and infrastructure needed to identify and develop novel tuberculosis (TB) vaccine candidates and move the most promising ones into human clinical trials. The results of those trials, coupled with advances from other TB studies, have paved the way for the next 10 years of research on TB vaccines, a critical component of TB control efforts, note scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

21 Mar 2012

Enrollment complete in HAL Allergy PURETHAL Mites Phase II trial for allergic rhinitis/rhinoconjunctivitis

HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II dose range finding study. This multi-centre, randomized, double-blind, placebo-controlled study in 250 patients with persistent allergic rhinitis / rhinoconjunctivitis will characterize the dose-response relationship of PURETHAL Mites in order to support the optimal dose in terms of clinical efficacy and safety.

21 Mar 2012

New drug makes chemotherapy more effective in treating acute myeloid leukemia

Doctors at Washington University School of Medicine in St. Louis have shown that a new drug makes chemotherapy more effective in treating acute myeloid leukemia, a cancer of the white blood cells. Instead of attacking these cells directly, the drug helps drive them out of the bone marrow and into the bloodstream, where they are more vulnerable to chemotherapy.

21 Mar 2012

Study tests new method of sound simulation for treating tinnitus

A new clinical trial is to test whether a pocket-sized device that uses sound simulation to reboot faulty 'wiring' in the brain could cure people with the debilitating hearing disorder tinnitus.

21 Mar 2012

PROLOR commences hGH-CTP Phase II trial in children with GHD

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency.

20 Mar 2012

Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.

20 Mar 2012